A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma-Reference-Cited by-同舟云学术

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma

Published:2017-02-13 Issue:11 Volume:123 Page:1979-1988
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Goyal Lipika¹²,Zheng Hui³,Yurgelun Matthew B.²⁴,Abrams Thomas A.²⁴,Allen Jill N.¹²,Cleary James M.²⁴,Knowles Michelle¹,Regan Eileen⁴,Reardon Amanda¹,Khachatryan Anna⁵,Jain Rakesh K.²⁵,Nardi Valentina²⁶,Borger Darrell R.²⁶,Duda Dan G.²⁵,Zhu Andrew X.¹²

Affiliation:

1. Department of Medicine; Massachusetts General Hospital Cancer Center; Boston Massachusetts

2. Harvard Medical School; Boston Massachusetts

3. Biostatistics Center; Massachusetts General Hospital; Boston Massachusetts

4. Dana-Farber Cancer Institute; Boston Massachusetts

5. Department of Radiation Oncology; Massachusetts General Hospital; Boston Massachusetts

6. Department of Pathology; Massachusetts General Hospital; Boston Massachusetts

Funder

ClinicalTrials.gov

National Institutes of Health

Exelixis

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections;Nagino;Ann Surg.,2013

2. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med.,2010

3. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study;Walter;Eur J Cancer.,2013

4. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma;Yoshikawa;Br J Cancer.,2008

5. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas;Hida;Anticancer Res.,1999

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma;Current Cancer Drug Targets;2024-07

2. Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells;International Immunopharmacology;2024-07

3. Immunological role of Gas6/TAM signaling in hemostasis and thrombosis;Thrombosis Research;2024-06

4. MET Oncogene Targeting for Cancer Immunotherapy;International Journal of Molecular Sciences;2024-06-01

5. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis;Future Oncology;2024-04